Overview

Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease

Status:
Withdrawn
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The investigators will be looking at the efficacy of the use of once daily use of low dose naltrexone (4.5mg) in subjects with symptomatic inflammatory bowel disease.
Phase:
Phase 2
Details
Lead Sponsor:
Santa Barbara Cottage Hospital
Treatments:
Naltrexone